Catalyst overview
Research summary
This catalyst tracks a Phase 1/2 data readout for LX2020 in Arrhythmogenic cardiomyopathy. The expected timing is based on the latest available company guidance and may change.
HEROIC-PKP2 trial. 9/12/24- Ongoing recruitment. 3/25- Interim data reported. 8/14/25- Interim clinical data update in H2 2025. 11/05/25:- Enrollment completed; low-dose cohort interim data shared; substantive Ph1/2 data update planned for January 2026. 01/12/26:- Preliminary HEROIC-PKP2 Ph1/2 data from 10 patients positive; 12-month high-dose data expected Q4 2026. 03/30/26:- HEROIC-PKP2 interim data detailed at ACC; dose-dependent PKP2 expression; Q4 2026 12-month update and 2026 FDA engagement. 05/11/26:- HEROIC-PKP2 Phase 1/2 shows good tolerability without complement activation; 12-month high-dose data still expected Q4 2026. 08/05/26:- FDA granted RMAT designation. Additional clinical and regulatory updates expected before year-end. 08/12/26:- RMAT designation and tolerability were reiterated. 12-month high-dose data update is expected in Q4 2026; FDA engagement is expected in 2026.
Verification
Confirm timing and program details against the company announcement or filing.